DBVT News and Press, DBV Technologies S.A. From 10/20/22

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euron...

Montrouge, France, October 3, 2022 DBV Technologies Announ ces Appointment of New Chair of its Audit Committee and A ppointment of Daniele Guyot-Caparros to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

French biotech DBV Technologies ( NASDAQ: DBVT ) on Wednesday said the U.S. FDA had put a partial clinical hold on its phase 3 clinical study evaluating its Viaskin Peanut patch for the treatment of peanut allergy in children aged 4 through 7. The FDA specified certain cha...

Montrouge, France, September 21, 2022 DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it recei...

Summary Two new Breakout Stocks for Week 38 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +116.8% YTD. This week two picks beat 10% gains in less than week with peak gains in BKKT +14.5% and CXM +12.5% with RIOT peaking ...

Montrouge, France, September 7, 2022 DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the M odified Viaskin Peanut P atch in Peanut - Allergic Children Ages 4 to 7 Years DBV has finalized t...

Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of Directors Names Kenneth Truitt, M.D., with over 25 years of clinical and regulatory experience across biotechnology and large pharmaceu...

DBV Technologies press release ( NASDAQ: DBVT ): Q2 GAAP EPS of -$0.35 misses by $0.03 . Revenue of $1.53M beats by $0.29M . Shares +3.19% AH. For further details see: DBV Technologies GAAP EPS of -$0.35 misses by $0.03, revenue of $1.53M beats by...

Montrouge, France, August 1, 2022 DBV Technologies Reports Second Quarter 2022 Financial Results DBV closes Q2 with a cash balance of $248M following recent ATM and PIPE offerings DBV continues to practice budget discipline measures; cash used in operating ...